PortfoliosLab logo
Puma Biotechnology, Inc. (PBYI)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US74587V1070

CUSIP

74587V107

IPO Date

Apr 24, 2012

Highlights

Market Cap

$148.83M

EPS (TTM)

$0.62

PE Ratio

4.84

PEG Ratio

0.03

Total Revenue (TTM)

$186.70M

Gross Profit (TTM)

$133.03M

EBITDA (TTM)

$46.42M

Year Range

$2.23 - $5.26

Target Price

$4.33

Short %

6.84%

Short Ratio

5.83

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Puma Biotechnology, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%NovemberDecember2025FebruaryMarchApril
-78.57%
302.72%
PBYI (Puma Biotechnology, Inc.)
Benchmark (^GSPC)

Returns By Period

Puma Biotechnology, Inc. had a return of -1.64% year-to-date (YTD) and -40.24% in the last 12 months. Over the past 10 years, Puma Biotechnology, Inc. had an annualized return of -34.20%, while the S&P 500 had an annualized return of 10.15%, indicating that Puma Biotechnology, Inc. did not perform as well as the benchmark.


PBYI

YTD

-1.64%

1M

-4.76%

6M

1.69%

1Y

-40.24%

5Y*

-23.29%

10Y*

-34.20%

^GSPC (Benchmark)

YTD

-6.06%

1M

-2.95%

6M

-4.87%

1Y

8.34%

5Y*

13.98%

10Y*

10.15%

*Annualized

Monthly Returns

The table below presents the monthly returns of PBYI, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-5.25%23.88%-17.32%1.35%-1.64%
20248.55%32.34%-14.79%-4.34%-24.06%-15.32%9.97%-30.26%2.00%11.76%18.95%-10.03%-29.56%
20231.65%-10.23%-19.95%-13.27%25.00%5.37%2.55%0.28%-27.55%-6.46%58.54%11.03%2.36%
2022-19.08%-6.50%25.22%-18.06%-17.80%46.91%2.81%-8.53%-11.57%-8.02%107.34%-6.42%39.14%
202114.42%-15.16%-2.41%1.44%7.00%-12.99%-18.08%0.66%-7.40%-27.25%-39.22%-1.94%-70.37%
2020-10.17%36.83%-21.52%19.08%1.59%2.15%-1.15%-0.19%-1.94%-17.05%34.41%-8.80%17.26%
201937.00%-0.25%39.48%-17.20%-53.95%-14.06%-24.08%11.40%0.14%-36.83%39.56%-7.80%-57.00%
2018-32.37%-2.24%4.13%-6.32%-16.94%11.71%-18.60%-8.72%4.32%-19.19%-37.27%-12.44%-79.41%
20175.54%13.27%1.36%9.14%88.42%14.25%8.75%-2.68%29.46%6.30%-16.81%-6.66%221.99%
2016-46.76%7.28%-34.41%4.49%23.13%-21.17%67.47%18.56%13.36%-42.88%12.40%-28.69%-60.84%
201511.52%0.91%10.84%-23.52%8.23%-40.27%-22.40%1.46%-18.02%9.37%-8.64%4.12%-58.58%
201414.18%-1.65%-10.42%-27.46%1.18%-13.65%235.94%17.50%-8.42%5.04%-9.41%-16.63%82.82%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PBYI is 24, meaning it’s performing worse than 76% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of PBYI is 2424
Overall Rank
The Sharpe Ratio Rank of PBYI is 2020
Sharpe Ratio Rank
The Sortino Ratio Rank of PBYI is 2323
Sortino Ratio Rank
The Omega Ratio Rank of PBYI is 2424
Omega Ratio Rank
The Calmar Ratio Rank of PBYI is 2525
Calmar Ratio Rank
The Martin Ratio Rank of PBYI is 2626
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Puma Biotechnology, Inc. (PBYI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for PBYI, currently valued at -0.57, compared to the broader market-2.00-1.000.001.002.003.00
PBYI: -0.57
^GSPC: 0.46
The chart of Sortino ratio for PBYI, currently valued at -0.51, compared to the broader market-6.00-4.00-2.000.002.004.00
PBYI: -0.51
^GSPC: 0.77
The chart of Omega ratio for PBYI, currently valued at 0.94, compared to the broader market0.501.001.502.00
PBYI: 0.94
^GSPC: 1.11
The chart of Calmar ratio for PBYI, currently valued at -0.42, compared to the broader market0.001.002.003.004.005.00
PBYI: -0.42
^GSPC: 0.47
The chart of Martin ratio for PBYI, currently valued at -1.05, compared to the broader market-5.000.005.0010.0015.0020.00
PBYI: -1.05
^GSPC: 1.94

The current Puma Biotechnology, Inc. Sharpe ratio is -0.57. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Puma Biotechnology, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2025FebruaryMarchApril
-0.57
0.46
PBYI (Puma Biotechnology, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Puma Biotechnology, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-98.91%
-10.07%
PBYI (Puma Biotechnology, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Puma Biotechnology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Puma Biotechnology, Inc. was 99.40%, occurring on May 11, 2022. The portfolio has not yet recovered.

The current Puma Biotechnology, Inc. drawdown is 98.91%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.4%Sep 19, 20141925May 11, 2022
-60.7%Jan 22, 201493Jun 4, 201434Jul 23, 2014127
-39.73%Sep 10, 201346Nov 12, 201316Dec 5, 201362
-21.43%Apr 27, 201226Jun 4, 201235Aug 20, 201261
-19.73%Oct 24, 201222Nov 27, 201233Jan 15, 201355

Volatility

Volatility Chart

The current Puma Biotechnology, Inc. volatility is 12.91%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%NovemberDecember2025FebruaryMarchApril
12.91%
14.23%
PBYI (Puma Biotechnology, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Puma Biotechnology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Puma Biotechnology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio
20.040.060.080.0100.0
PBYI: 4.8
The chart displays the Price-to-Earnings (P/E) ratio for PBYI, comparing it with other companies in the Biotechnology industry. Currently, PBYI has a P/E ratio of 4.8. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
2.04.06.08.010.0
PBYI: 0.0
The chart shows the Price/Earnings to Growth (PEG) ratio for PBYI compared to other companies in the Biotechnology industry. PBYI currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
20.040.060.080.0100.0
PBYI: 0.6
This chart shows the Price-to-Sales (P/S) ratio for PBYI relative to other companies in the Biotechnology industry. Currently, PBYI has a P/S ratio of 0.6. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
2.04.06.08.010.0
PBYI: 1.6
The chart illustrates the Price-to-Book (P/B) ratio for PBYI in comparison with other companies in the Biotechnology industry. Currently, PBYI has a P/B value of 1.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items